Burden of Wet Age-Related Macular Degeneration and Its Economic Implications in Singapore in the Year 2030
Authors:
- 24 June 2016
- journal article
- research article
- Published by Taylor & Francis in Ophthalmic Epidemiology
- Vol. 23 (4) , 232-237
Abstract
Purpose: To estimate the prevalence of wet age-related macular degeneration (AMD) in Singapore in the year 2030. This projection will help in planning appropriate care provision and build health services capacity to cater to the increasing healthcare demand in 2030. Methods: The number of AMD patients aged 40–79 years from all Singaporeans was estimated using prevalence rates from a local study and using the United Nations population projections for Singapore to 2030. Age-specific mortality was accounted for. Additionally, two main scenarios were presented: (1) Projected number of wet AMD cases if patients were not taking preventive antioxidant vitamins; (2) projected number of wet AMD cases if patients were taking preventive antioxidant vitamins. Based on these scenarios, the economic burden was calculated. The number of quality-adjusted life years (QALYs) gained as a result of improvement in visual acuity (VA) due to anti-vascular endothelial growth factor (VEGF) treatment was also calculated. Results: An estimated growth of 42% in the number of wet AMD cases is expected by 2030. The estimated economic burden of wet AMD in 2030 for scenarios 1 and 2 is Singapore $203.1 million and $162.9 million, respectively. The QALYs gained as a result of improved VA from wet AMD treatment ranged from 10,114.4 to 14,058.8 over a 5-year period for the 2030 cohort. Conclusion: The burden of wet AMD is set to increase over the next 15 years. Appropriate measures to build healthcare capacity and plan for this expected surge in patients should be a priority in Singapore.Keywords
This publication has 20 references indexed in Scilit:
- Long-Term Effects of Vitamins C and E, β-Carotene, and Zinc on Age-related Macular DegenerationOphthalmology, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Projected prevalence of age‐related macular degeneration in Scandinavia 2012–2040Acta Ophthalmologica, 2012
- Global estimates of visual impairment: 2010British Journal of Ophthalmology, 2011
- Cost‐utility analysis of bevacizumab versus ranibizumab in neovascular age‐related macular degeneration using a Markov modelJournal of Evaluation in Clinical Practice, 2010
- The Prevalence of Age-Related Macular Degeneration in AsiansOphthalmology, 2010
- Forecasting Age-Related Macular Degeneration Through the Year 2050Archives of Ophthalmology (1950), 2009
- Why cost-of-illness studies are important and inform policyVascular Medicine, 2008
- The Economic Burden of Major Adult Visual Disorders in the United StatesArchives of Ophthalmology (1950), 2006
- The epidemiology of age related eye diseases in AsiaBritish Journal of Ophthalmology, 2006